The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC

NCT03905967 ·Status: UNKNOWN ·Phase: PHASE3

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

NCT03791918 ·Status: WITHDRAWN ·Phase: PHASE3

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

NCT06609850 ·Status: RECRUITING ·Phase: NA

TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

NCT05220020 ·Status: UNKNOWN ·Phase: PHASE3

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

NCT05608213 ·Status: RECRUITING ·Phase: PHASE3

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

NCT04599790 ·Status: COMPLETED ·Phase: PHASE2

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)

NCT04560751 ·Status: UNKNOWN

SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)

NCT05718232 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT03838796 ·Status: UNKNOWN ·Phase: NA

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

NCT03803254 ·Status: WITHDRAWN ·Phase: PHASE2

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

NCT03801499 ·Status: WITHDRAWN ·Phase: PHASE2

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

NCT06519721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

NCT04961918 ·Status: UNKNOWN ·Phase: PHASE2

Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma

NCT05609695 ·Status: UNKNOWN

Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer

NCT04656249 ·Status: COMPLETED ·Phase: PHASE2

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

NCT04053972 ·Status: UNKNOWN ·Phase: PHASE3

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

NCT05444478 ·Status: RECRUITING ·Phase: NA

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

NCT05985798 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

NCT05484908 ·Status: RECRUITING ·Phase: NA

Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

NCT04791176 ·Status: COMPLETED ·Phase: PHASE2

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

NCT05555316 ·Status: UNKNOWN ·Phase: PHASE2

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

NCT05842317 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma

NCT04490694 ·Status: UNKNOWN ·Phase: PHASE2

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

NCT06904196 ·Status: RECRUITING ·Phase: PHASE2

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

NCT04997850 ·Status: COMPLETED ·Phase: PHASE1/PHASE2